Updated 04:19 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,872.70 -0.35% CL 84.95 -4.08% BTC 64,888.19 -0.64%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,873 −0.35% BTC $64,888 −0.64% VIX 22.91 +18.70% latest tape · as of 04:19 UTC
The Screen · Healthcare · Medical Devices

SI-BONE Inc

SIBN · NASDAQ · USD · Market cap $771M · 376 employees

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.

FAIL · Does not pass the screen
23.44 USD

Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago

Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price23.44 USD at the 13 Nov 2026 close
  • Our value readFair vs our fair value, as of 13 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.01)
  • Last reviewed13 Nov 2026 (4 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $18.00 to $32.00, base estimate $24.00 (screen dated 2026-11-13).

Current read
Markup ?
Fair · screened 2026-11-13
  • Trend Markup
  • Insiders insiders sold, $1,897,643, latest filing 2026-11-04
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.01, read 2026-11-14
  • Ethical does not pass the values gate
Price23.44 USD
Fair value24.00
Ethical score70.0/100
Value readFairas of 13 Nov 2026
Our investment reviews on this name
2026-11-09Read Markup24.24-3.3% to today Accumulation gives way to Markup after a 14% rise in 8 days
2026-11-01Read Accumulation21.23+10.4% to today ✓Markup gives way to Accumulation after a 9% rise in 6 days
2026-10-26Read Markup19.47+20.4% to today ✓Accumulation gives way to Markup after an 8% rise in 2 weeks
2026-10-11Read Accumulation18.09+29.6% to today ✓Markdown gives way to Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

SI-BONE Inc holds its Markup at $23.44. The statistical read favours the sellers, held for 3 days.

As held on the ledger · 2026-11-13
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 3 days
Price at the screen$23.44
ValuationN/A trailing · -49.25 forward price to earnings
Values screenFAIL · score 70.0
Beta0.67
The Workings

Five Screens, Shown in Full

Does not pass. Interest-bearing securities

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 15.38% Below 33% Interest-bearing debt is just 15.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 44.26% Below 33% Interest-bearing cash and securities are 44.3% of assets, above the one-third limit. Fail
Receivables 30.25% Below 49% Money owed to the company is 30.2% of assets, under the 49% limit. Pass
Revenue purity 3.02% Below 5% Only 3.0% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

SI-BONE's business is fine, but its cash and interest-bearing securities are about 44% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when SIBN's ethical verdict changes

Today SIBN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades at roughly a 2% discount to our $24.00 fair value, none competitive moat, 11.20% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

18.00Conservative24.00Base case32.00Growth case 23.44Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 2.3% discount to the base estimate.

The Street's Range
18.00Street low 24.00Street average 32.00Street high 23.44Price

Third-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +2% from the screen price.

Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.

Price History & Projections

Where our models see it going: fair-value estimate $24.00, with a range of $18.00 to $32.00, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it is worth knowing

A quality business: a none moat. It trades close to our $24.00 fair value, so the easy discount is gone; you would be paying up for the quality.

The fundamentals · plain-English read
Forward P/E-49.3x
EPS, trailing-0.39
EPS, forward-0.35
Revenue growth+11.2%steady growth
Profit margin-8.1%currently unprofitable
Return on equity-9.6%not currently earning a positive return on equity
FCF yield-0.34%
Debt to equity0.24minimal debt: a conservative balance sheet
Current ratio9.99comfortably covers its short-term bills
Beta0.67steadier than the market
Short interest, float0.16%
52-week range11.48 - 21.89
MoatNONE
Market cap$771M
Employees376

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

SIBN trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-16 Markup $23.44 -3.3% Entry 19

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 43% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter.

2026-11-09 Markup · changed $24.24 +14.2% Entry 18

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 43% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. Since the last review it entered the Titan Ethical 500; dropped out of the Titan Ethical 500; its composite score eased.

2026-11-02 Accumulation $21.23 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Accumulation · changed $21.23 -1.2% Entry 16

The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Markup $21.48 +0.0% Entry 15

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Markup $21.48 +0.0% Entry 14

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Markup $21.48 +10.3% Entry 13

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Markup $19.47 +0.0% Entry 12

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Markup $19.47 +0.0% Entry 11

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Markup · changed $19.47 +0.0% Entry 10

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (8 analysts) rates it none, with a mean price target of $24. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in SIBN's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · SIBN
DateInsiderTitleTypeSharesValue
2026-11-04 Pisetsky Michael A. SVP, Ops, Adm, Chief Legal Ofr S - Sale+OE 36,241 $901,844
2026-11-04 Francis Laura CEO S - Sale 75,000 $1,897,643
2026-11-04 Pisetsky Michael A. SVP, Ops, Adm, Chief Legal Ofr S - Sale 36,241 $898,802
2026-11-04 Maheshwari Anshul Chief Op, Financial Officer S - Sale 3,247 $81,175
2026-11-02 Dunn Jeffrey W Dir S - Sale+OE 20,000 $417,820
2026-10-29 Pisetsky Michael A. SVP, Ops, Adm, Chief Legal Ofr S - Sale 29,665 $655,745
2026-10-29 Maheshwari Anshul Chief Op, Financial Officer S - Sale 3,738 $84,105
2026-10-12 Francis Laura CEO S - Sale 38,006 $762,013

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $11.61 +32.4% · $1,324 +32.4%
2 months $12.84 +19.7% · $1,197 +19.7%
3 months $13.82 +11.2% · $1,112 +11.2%
6 months $18.82 -18.3% · $817 -18.3%
1 year $19.10 -19.5% · $805 -19.5%
2 years $13.15 +16.9% · $1,169 +16.9%
3 years $28.01 -45.1% · $549 -45.1%
5 years $31.39 -51.0% · $490 -51.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever SIBN does next, these words stay.

SI-BONE Inc · SIBN · Markup · $23.44
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.